Cancer immunotherapy, mainly including immune checkpoints-targeted therapy and the
adoptive transfer of engineered immune cells, has revolutionized the oncology landscape as …

Cancer immunotherapy has been accompanied by promising results over the past few
years. Programmed Cell Death Protein 1 (PD-1) plays a vital role in inhibiting immune …

Colorectal cancer (CRC), and breast, ovarian, pancreatic and prostate cancers are generally
considered as low immune-reactive cancers that represent either limited infiltration of …

Immunotherapy has revolutionized colon cancer treatment. Immune checkpoint inhibitors
(ICIs) have shown clinical benefits for colon cancer patients, especially those with high …

Simple Summary In breast cancer development, the expression of Ki-67 is strongly
associated with cancer proliferation and is a known indicator of prognosis and outcome. Ki …

Background. Innovative drugs targeting the PD1/PD-L1 axis have opened promising
scenarios in modern cancer therapy. Plenty of assays and scoring systems have been …

Colorectal cancer (CRC) is one of the most prevalent cancers, with more than one million
new cases every year. In the last few decades, several advancements in therapeutic and …

Maintenance of gastrointestinal health is challenging as it requires balancing multifaceted
processes within the highly complex and dynamic ecosystem of the gastrointestinal tract …

Simple Summary Breast cancer (BC) is the most common malignant neoplasm in women
and one of the leading causes of cancer death in women worldwide. Programmed death …

PD‑L1 inhibitors are widely used in tumor immunotherapy, but their mechanism in colorectal
cancer remains unclear. The present study aimed to investigate the mechanisms underlying …